RediNews
ETFs Holding LGND »    LGND Historical Stock Prices »
LGND News Video: Wed, Nov 18, 2015, 1:07 PM — Wednesday's ETF Movers: PJP, GDXJ


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Ligand Pharmaceuticals is a biopharmaceutical company, engaged in developing and acquiring technologies to discover and develop medicines. Co. has partnerships and license agreements with over 95 pharmaceutical and biotechnology companies, and over 160 different programs under license with Co. is in various stages of commercialization and development. Co. has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others. Co.'s partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others. Self directed investors in Ligand Pharmaceuticals Inc will be interested in keeping up with all Ligand Pharmaceuticals Inc news they can find, both LGND news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on LGND. At RediNews, we simplify this task by presenting both LGND news releases originating from Ligand Pharmaceuticals Inc itself, and LGND news from a variety of media outlets. Visitors can browse this news online and through our LGND RSS news feed.

LGND News

LGND News — Articles, Videos, & Press Releases

3 Healthcare Stocks to Buy on Renewed Obamacare Repeal Talks
Tuesday, September 19, 2017, 1:41 PM — Zacks
Glaxo's Shingles Candidate Gets Positive FDA Committee Vote
Thursday, September 14, 2017, 9:25 AM — Zacks
Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable
Tuesday, September 12, 2017, 8:15 AM — Zacks
The LGND Paradox: Analysts Bullish But Forecast -1.71% Fall
Friday, September 8, 2017, 9:22 AM — ETF Channel
Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth
Friday, September 8, 2017, 7:54 AM — Zacks
Alnylam Shares Plunge on Patient Death, Dosing Suspended
Friday, September 8, 2017, 7:53 AM — Zacks
Ligand (LGND) Up 9.6% Since Earnings Report: Can It Continue?
Thursday, September 7, 2017, 1:10 AM — Zacks
Ligand (LGND) Diabetes Candidate Positive in Phase II Study
Wednesday, September 6, 2017, 8:03 AM — Zacks
Insmed Incorporated (INSM) Catches Eye: Stock Soars 119.6%
Wednesday, September 6, 2017, 6:31 AM — Zacks
4 Biotech Stocks to Improve Your Portfolio's Health
Tuesday, September 5, 2017, 12:26 PM — Zacks
Amgen Gets EU Nod to Expand Hyperparathyroidism Drug Label
Friday, September 1, 2017, 9:11 AM — Zacks
Top Ranked Momentum Stocks to Buy for August 30th
Wednesday, August 30, 2017, 7:16 AM — Zacks
Vertex's Cystic Fibrosis Combo Gets Priority Review in U.S.
Friday, August 25, 2017, 8:51 AM — Zacks
4 Biotech Stocks to Add to your Portfolio Post Q2 Earnings
Tuesday, August 22, 2017, 8:10 AM — Zacks
Strength Seen in Myovant Sciences (MYOV): Stock Soars 16.1%
Friday, August 18, 2017, 6:58 AM — Zacks
Can Ligand's Captisol Deals Boost Growth in the Long Run?
Tuesday, August 15, 2017, 8:09 AM — Zacks
Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised
Tuesday, August 8, 2017, 9:14 AM — Zacks
Can Ligand (LGND) Pull a Surprise This Earnings Season?
Tuesday, August 1, 2017, 2:50 PM — Zacks
Ligand Signs Agreement with Amgen, Grants Rights to Captisol
Tuesday, July 18, 2017, 8:37 AM — Zacks
Ligand Gets Milestone Payment on Partner Drug FDA Approval
Wednesday, June 21, 2017, 3:40 PM — Zacks
Key FDA Events to Watch Out for in Jun 2017
Monday, June 5, 2017, 5:47 AM — Zacks
Ligand (LGND) Signs Licensing Deal with xCella Biosciences
Wednesday, May 31, 2017, 2:59 PM — Zacks
The Math Shows IYH Can Go To $174
Friday, May 19, 2017, 9:40 AM — ETF Channel
5 Joel Greenblatt Holdings Attracting Short Sellers
Wednesday, May 10, 2017, 1:11 PM — Dividend Channel
Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates
Wednesday, May 10, 2017, 8:06 AM — Zacks
Can Ligand (LGND) Spring a Surprise this Earnings Season?
Thursday, May 4, 2017, 8:29 AM — Zacks
Notable Tuesday Option Activity: IAC, LGND, WATT
Tuesday, May 2, 2017, 3:24 PM — Stock Options Channel
Short Sellers Drawn To These Five Joel Greenblatt Holdings
Wednesday, April 26, 2017, 1:26 PM — Dividend Channel
LGND Makes Bullish Cross Above Critical Moving Average
Tuesday, April 25, 2017, 11:39 AM — Market News Video
Implied PJP Analyst Target Price: $72
Friday, March 31, 2017, 8:53 AM — ETF Channel
Ligand Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for LGND
Friday, March 10, 2017, 4:23 PM — Market News Video
PJP, AKRX, LGND, MYL: ETF Outflow Alert
Thursday, March 9, 2017, 11:10 AM — ETF Channel
New Strong Sell Stocks for March 7th
Tuesday, March 7, 2017, 8:12 AM — Zacks
Noteworthy Thursday Option Activity: LGND, LXRX, REGN
Thursday, March 2, 2017, 3:24 PM — Stock Options Channel
Oversold Conditions For Ligand Pharmaceuticals
Friday, February 24, 2017, 12:07 PM — Dividend Channel
Sum Up The Parts: PJP Could Be Worth $70
Friday, February 24, 2017, 9:38 AM — ETF Channel
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates
Friday, February 24, 2017, 8:52 AM — Zacks
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More
Wednesday, February 22, 2017, 7:29 AM — Zacks
Forget Alexion, Buy these 4 Biotech Stocks Instead
Monday, February 20, 2017, 6:52 AM — Zacks
Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?
Thursday, February 16, 2017, 7:29 AM — Zacks
4 Drug Stocks that are Broker Favorites
Tuesday, February 7, 2017, 6:41 AM — Zacks
The Math Shows PJP Can Go To $70
Tuesday, January 24, 2017, 9:06 AM — ETF Channel
Notable Wednesday Option Activity: RGR, RAD, LGND
Wednesday, January 18, 2017, 3:28 PM — Stock Options Channel
Ligand (LGND) Signs Licensing Deals with Ono and Novartis
Friday, December 23, 2016, 7:14 AM — Zacks
Noteworthy Thursday Option Activity: ACHC, DOW, LGND
Thursday, December 22, 2016, 3:23 PM — Stock Options Channel
Notable Wednesday Option Activity: LGND, TER, OSTK
Wednesday, December 14, 2016, 11:37 AM — Stock Options Channel
PJP, LCI, CELG, LGND: ETF Outflow Alert
Monday, December 12, 2016, 10:47 AM — ETF Channel
How The Pieces Add Up: IYH Targets $169
Wednesday, November 30, 2016, 9:11 AM — ETF Channel
Ligand's Partner Retrophin Provides New Data on Sparsentan
Tuesday, November 22, 2016, 8:02 AM — Zacks
Ligand (LGND) Q3 Earnings Down Y/Y, Lowers '16 Guidance
Friday, November 4, 2016, 6:06 AM — Zacks
Ligand Pharmaceuticals is Now Oversold (LGND)
Thursday, November 3, 2016, 4:33 PM — Dividend Channel
Sum Up The Parts: EWSC Could Be Worth $48
Friday, October 28, 2016, 9:37 AM — ETF Channel
Ligand (LGND) Q3 Earnings: Is the Stock Likely to Disappoint?
Friday, October 28, 2016, 7:22 AM — Zacks
Ligand Partner Melinta Therapeutics Submits NDA for Baxdela
Tuesday, October 25, 2016, 2:32 PM — Zacks
New Strong Sell Stocks for October 5th
Wednesday, October 5, 2016, 6:53 AM — Zacks
Amgen's Multiple Myeloma Drug Kyprolis Fails in Phase III
Wednesday, September 28, 2016, 5:10 AM — Zacks
Ligand Pharmaceuticals Enters Oversold Territory (LGND)
Tuesday, September 27, 2016, 4:27 PM — Dividend Channel
Notable Tuesday Option Activity: GILD, LGND, NHI
Tuesday, September 27, 2016, 3:26 PM — Stock Options Channel
Analysts Forecast 14% Upside For IYH
Tuesday, September 27, 2016, 9:46 AM — ETF Channel
Kite Pharma Reports Favorable Data from Lymphoma Study
Tuesday, September 27, 2016, 8:28 AM — Zacks
GW Pharma Attains 52-Week High on Positive Epidiolex Data
Tuesday, September 27, 2016, 7:04 AM — Zacks
Regeneron, Sanofi Skin Disease Drug Under Priority Review
Monday, September 26, 2016, 1:55 PM — Zacks
Endo Appoints New CEO, Keeps Q3 & '16 View, Stock Jumps
Monday, September 26, 2016, 9:12 AM — Zacks
Ligand Inks CNS License Agreement with Seelos Therapeutics
Friday, September 23, 2016, 8:03 AM — Zacks
Teva Reports Positive Phase III Tardive Dyskinesia Data
Friday, September 23, 2016, 7:33 AM — Zacks
Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology
Monday, September 19, 2016, 8:26 AM — Zacks
Novartis Reports Positive Phase II Data on Migraine Drug
Friday, September 16, 2016, 7:21 AM — Zacks
Epizyme Receives Milestone from Glaxo for Lymphoma Drug
Friday, September 16, 2016, 7:05 AM — Zacks
Commit To Purchase Ligand Pharmaceuticals At $100, Earn 10.8% Annualized Using Options
Thursday, September 15, 2016, 11:41 AM — Stock Options Channel
Roche Ocrevus Positive in Phase III Multiple Sclerosis Trials
Thursday, September 15, 2016, 7:37 AM — Zacks
Shire's Immunodeficiency Treatment Cuvitru Gets FDA Approval
Thursday, September 15, 2016, 7:00 AM — Zacks
Ligand (LGND) Commences Phase II Type II Diabetes Study
Wednesday, September 14, 2016, 7:22 AM — Zacks
5 Biotech Stocks That Are Broker Favorites
Tuesday, September 13, 2016, 7:43 AM — Zacks
Ligand/Retrophin Rare Disease Drug Positive in Phase II
Thursday, September 8, 2016, 5:37 AM — Zacks
LGND Makes Bullish Cross Above Critical Moving Average
Wednesday, September 7, 2016, 4:23 PM — Market News Video
Short Interest Falls 11% For LGND
Thursday, August 25, 2016, 3:50 PM — Market News Video
Ligand Pharmaceuticals is Now Oversold (LGND)
Wednesday, August 17, 2016, 12:00 PM — Dividend Channel
Ligand Pharmaceuticals (LGND) Shares Cross Below 200 DMA
Wednesday, August 17, 2016, 11:25 AM — Market News Video
We Did The Math PTH Can Go To $54
Wednesday, August 17, 2016, 7:39 AM — ETF Channel
5 Stocks to Play Momentum the Driehaus Way
Thursday, August 11, 2016, 7:53 AM — Zacks
Inovio (INO) Q2 Loss in Line with Estimates, Revenues Top
Tuesday, August 9, 2016, 7:41 AM — Zacks
Endocyte (ECYT) Q2 Loss Wider than Expected (Revised)
Tuesday, August 9, 2016, 3:31 AM — Zacks
Ligand (LGND) Q2 Earnings Decline Y/Y, Maintains View
Friday, August 5, 2016, 4:48 AM — Zacks
Ligand (LGND) Beats Q2 Earnings, Revenues Up Y/Y
Thursday, August 4, 2016, 7:41 AM — Zacks
Ligand (LGND) Q2 Earnings: What's in Store for the Stock?
Tuesday, August 2, 2016, 5:18 AM — Zacks
Ligand Pharmaceuticals Reaches Analyst Target Price
Thursday, July 21, 2016, 9:51 AM — ETF Channel
Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 5.5%
Thursday, July 21, 2016, 6:25 AM — Zacks
Ligand Pharmaceuticals Larger Than S&P 500 Component Endo International
Tuesday, July 19, 2016, 4:37 PM — Market News Video
Ligand (LGND) Signs Deal with Gilead for OmniAb Technology
Monday, July 11, 2016, 9:00 AM — Zacks
7 Profitable Medical Stocks Ranked as Buys Now
Tuesday, June 21, 2016, 1:52 PM — Zacks
7 Biotech Stocks that are Buys Right Now
Friday, June 17, 2016, 9:00 AM — Zacks
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Wednesday, June 8, 2016, 8:52 AM — Zacks
Analysts See 12% Gains Ahead For The Holdings of PWC
Wednesday, June 1, 2016, 7:18 AM — ETF Channel
Ligand (LGND) Beats Q1 Earnings and Revenue Estimates
Wednesday, May 4, 2016, 5:56 AM — Zacks
Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More
Tuesday, May 3, 2016, 7:08 AM — Zacks
Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Monday, May 2, 2016, 9:09 AM — Zacks
Will Ligand Pharmaceuticals (LGND) Continue to Surge Higher?
Friday, April 8, 2016, 6:27 AM — Zacks
Analysts Anticipate 10% Gains Ahead For The Holdings of EZM
Thursday, March 24, 2016, 7:56 AM — ETF Channel
Gilead and 4 Other Buy Stocks in the Biotech Industry
Tuesday, March 22, 2016, 7:05 AM — Zacks
Bullish Two Hundred Day Moving Average Cross - LGND
Friday, February 26, 2016, 11:35 AM — Market News Video
Analysts Predict 16% Gains Ahead For The Holdings of FAD
Monday, February 22, 2016, 8:03 AM — ETF Channel
Bristol-Myers Inks Immuno-Oncology Deal with Dana-Farber
Wednesday, February 17, 2016, 3:40 PM — Zacks
Gilead's HCV Drug Harvoni Approved in Two More Indications
Wednesday, February 17, 2016, 2:25 PM — Zacks
Merck (MRK) Gets CRL for Zetia & Vytorin sNDA from FDA
Tuesday, February 16, 2016, 3:25 PM — Zacks
Clovis' (CLVS) Rociletinib to Face FDA Advisory Panel in April
Monday, February 15, 2016, 2:00 PM — Zacks
Eli Lilly's Alimta Gets Negative Ruling in UK Patent Lawsuit
Monday, February 15, 2016, 1:10 PM — Zacks
Alnylam (ALNY) Reports Wider Q4 Loss; Revenues Miss
Friday, February 12, 2016, 11:00 AM — Zacks
Incyte (INCY) Beats on Q4 Earnings and Revenue Estimates
Friday, February 12, 2016, 9:55 AM — Zacks
Alkermes' ALKS 3831 in 2nd Phase III Study for Schizophrenia
Thursday, February 11, 2016, 1:15 PM — Zacks
Ligand (LGND) Beats on Q4 Earnings, Raises 2016 Outlook
Thursday, February 11, 2016, 11:02 AM — Zacks
INSYS (INSY) Initiates Phase II Study for Infantile Spasms
Wednesday, February 10, 2016, 3:40 PM — Zacks
Actelion (ALIOF) Misses Q4 Earnings, Revenue Estimates
Wednesday, February 10, 2016, 2:23 PM — Zacks
Cytori Tanks on Unfavorable Data from Osteoarthritis Study
Tuesday, February 9, 2016, 3:45 PM — Zacks
Epizyme's Tazemetostat Gets Orphan Drug Status in the U.S.
Tuesday, February 9, 2016, 3:40 PM — Zacks
Cempra Reports Positive Data on Antibiotic Solithromycin
Tuesday, February 9, 2016, 1:10 PM — Zacks
Vertex (VRTX) Down on CRL for Kalydeco Label Expansion
Monday, February 8, 2016, 4:38 PM — Zacks
Bristol-Myers' Daklinza-Sovaldi Label Expanded by the FDA
Monday, February 8, 2016, 2:50 PM — Zacks
Ligand Pharmaceuticals (LGND): Q4 Earnings Preview
Monday, February 8, 2016, 9:50 AM — Zacks
ImmunoGen/Merck Collaborate for Ovarian Cancer Study
Friday, February 5, 2016, 4:00 PM — Zacks
Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies
Friday, February 5, 2016, 2:50 PM — Zacks
Synthetic Biologics Tanks on Unfavorable Trimesta Data
Wednesday, February 3, 2016, 3:25 PM — Zacks
LGND Makes Notable Cross Below Critical Moving Average
Wednesday, February 3, 2016, 11:48 AM — Market News Video
Avalanche (AAVL) Set to Acquire Annapurna Therapeutics
Tuesday, February 2, 2016, 4:28 PM — Zacks
Exelixis' Cabozantinib Positive in Renal Cell Carcinoma Study
Tuesday, February 2, 2016, 3:50 PM — Zacks
First Week of March 18th Options Trading For Ligand Pharmaceuticals (LGND)
Tuesday, February 2, 2016, 10:59 AM — Stock Options Channel
Spectrum (SPPI) Initiates Phase III Study on SPI-2012
Monday, February 1, 2016, 6:21 PM — Zacks
Bristol-Myers' Daklinza-Sovaldi Label Expanded in the EU
Friday, January 29, 2016, 5:52 PM — Zacks
SurModics' (SRDX) Q1 Earnings & Revenues Beat Estimates
Friday, January 29, 2016, 10:40 AM — Zacks
Alkermes Initiates Early-Stage Study on Alzheimer's Drug
Wednesday, January 27, 2016, 2:25 PM — Zacks
MannKind (MNKD) Signs Deal with Receptor Life Sciences
Friday, January 22, 2016, 2:20 PM — Zacks
Alkermes Hit 52-Week Low on Unfavorable Phase III Data
Friday, January 22, 2016, 2:10 PM — Zacks
Cymabay Gives Update on Phase III Program on Arhalofenate
Thursday, January 21, 2016, 2:15 PM — Zacks
Incyte Reports Baricitinib NDA Filing for Rheumatoid Arthritis
Wednesday, January 20, 2016, 2:25 PM — Zacks
Galapagos (GLPG) Gives Update on Cystic Fibrosis Program
Wednesday, January 20, 2016, 2:15 PM — Zacks
Impax's Emverm Approved for Parasitic Worm Infestations
Tuesday, January 19, 2016, 2:00 PM — Zacks
BioMarin's DMD Drug Kyndrisa Receives CRL from the FDA
Friday, January 15, 2016, 1:25 PM — Zacks
Ligand, Emergent BioSolutions Tie Up for OmniAb Technology
Thursday, January 14, 2016, 3:35 PM — Zacks
Esperion (ESPR) Initiates Phase III Study for Hyperlipidemia
Thursday, January 14, 2016, 2:30 PM — Zacks
Alnylam Provides Update on RNAi Therapeutics Pipeline
Wednesday, January 13, 2016, 3:20 PM — Zacks
SurModics Buys NorMedix for $14M, Adjusts 2016 Outlook
Tuesday, January 12, 2016, 2:22 PM — Zacks
BioMarin Reveals Interim Data from Pompe Disease Study
Tuesday, January 12, 2016, 1:50 PM — Zacks
Acorda's Ampyra Ends 2015 on Strong Note, Pipeline in Focus
Tuesday, January 12, 2016, 8:50 AM — Zacks
Orexigen Targets Profitability by 2018, Focus on Contrave
Tuesday, January 12, 2016, 8:30 AM — Zacks
Notable Two Hundred Day Moving Average Cross - LGND
Monday, January 11, 2016, 4:44 PM — Market News Video
AbbVie Starts Phase III Program on ABT-494 for RA Treatment
Monday, January 11, 2016, 1:30 PM — Zacks
AbbVie's Viekira Pak sNDA Accepted with Priority Review
Friday, January 8, 2016, 10:50 AM — Zacks
Vical's VL-2397 Gets Orphan Status for Invasive Aspergillosis
Thursday, January 7, 2016, 1:50 PM — Zacks
5 Biotech Stocks That Doubled in 2015
Thursday, January 7, 2016, 11:17 AM — Zacks
Bristol-Myers' Opdivo/Yervoy sBLA to Face Final Decision
Monday, January 4, 2016, 1:50 PM — Zacks
Alkermes Upgraded to Hold on Encouraging Portfolio Update
Monday, January 4, 2016, 1:45 PM — Zacks
15 Best Stocks to Ring Out the Old, Ring In the New
Thursday, December 31, 2015, 8:20 AM — Zacks
Ligand (LGND) Upgraded to Buy, Perfect for Your Portfolio
Wednesday, December 30, 2015, 3:35 PM — Zacks
Ligand (LGND) Beats on Q3 Earnings, Lowers 2015 Outlook
Tuesday, November 10, 2015, 9:32 AM — Zacks
What Awaits Ligand Pharmaceuticals (LGND) in Q3 Earnings?
Thursday, November 5, 2015, 3:25 PM — Zacks
Spectrum Pharmaceuticals' Evomela Gets CRL in the U.S.
Friday, October 23, 2015, 10:12 AM — Zacks
Ligand, SAGE Captisol Partnership to Also Include SAGE-689
Wednesday, September 30, 2015, 2:55 PM — Zacks
First Week of LGND October 16th Options Trading
Monday, September 28, 2015, 11:01 AM — Stock Options Channel
Novartis' (NVS) Promacta Label Further Expanded in U.S.
Wednesday, August 26, 2015, 2:45 PM — Zacks
LGND is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

ARQL News
CRTX News
STAA News
BABY News
MDXG News
CMN News
MDCO News
CYTX News
ACOR News
TSRO News

RediNews would like to be your web content provider of choice for news feeds by stock ticker symbol, or by market sector. An ideal complement to other financial content like stock quotes and charts, our news gives your users what they want — to see what is being published about the stocks they own, and what the companies themselves are publishing. Simply navigate to any RediNews news page by specific ticker symbol, then click the RSS icon for any news page to reach the associated RSS feed (the icon will look like this): . There is no charge to use our feeds, they are available to you for free.

LGND News | www.RediNews.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.RediNews.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.